Adjusting Outcome Measures to Assess Rehabilitation in Pulmonary Hypertension - Pulmonology Advisor

Adjusting Outcome Measures to Assess Rehabilitation in Pulmonary Hypertension - Pulmonology Advisor

Adjusting Outcome Measures to Assess Rehabilitation in Pulmonary Hypertension - Pulmonology Advisor

Posted: 23 Oct 2020 08:25 AM PDT

In patients with pulmonary hypertension (PH) undergoing rehabilitation, greater inclusion of outcome measures that reflect activity and participation in society, rather than body functions/structure, is needed to facilitate accurate assessment of the wider effect of this intervention. A systematic review of the literature was performed to identify studies of rehabilitation conducted in patients with PH between 2006 and 2019. Results of the analysis were published in the Annals of the American Thoracic Society.

Recognizing that the World Health Organization International Classification for Functioning, Disability and Health identifies 3 different health domains — body functions/structures, activity, and participation in society — investigators sought to ensure that the study end points used to evaluate patients with PH undergoing rehabilitation were reflective of all 3 of these measures. Searches were performed across 5 databases and yielded a total of 2564 articles, with 34 meeting eligibility criteria.

A total of 50 different outcome measures were identified. The studies used an average of 5 outcome measures (minimum=1; maximum=9), providing a total of 176 instances of outcome measure usage across the studies. The most often used measures were exercise testing (n=56), quality of life (QoL) measures (n=31), and biomarkers (n=23), with a few different outcomes appearing within each category. In 32 of the 34 studies, the 6-minute walking distance (6MWD) was used as a gauge. Of the remaining 2 studies, 1 used cardiopulmonary exercise testing and 1 used attainable treadmill speed. In 26% (9 of 34) of the studies, no QoL measure was used. In fact, 2 of these studies used symptom-specific patient-reported outcomes.

A majority of the publications evaluated (94%) had been conducted in the last 10 years, which reflects an increased number of randomized controlled studies during that time. The studies were most often carried out in patients with pulmonary arterial hypertension (56%) or in those with PH of a nonspecified cause (29%). Although the rehabilitation interventions used differed in their content and length, they were most often a type of whole-body exercise training that involved a combination of cardiovascular, respiratory, and resistance training, along with education about the disease and management of its symptoms.

Continue Reading

Of the 34 studies included in the review, 48% of the instances of outcome usage were measures of body function/structure, 33% were measures of activity, and 18% were measures of participation. In fact, 7 of the 34 studies did not include any measures of participation.

The investigators concluded that future studies of rehabilitation in individuals with PH need to evaluate change across a broad spectrum of patients' lives. Once ideal measures are used to capture rehabilitation outcomes, this will allow the design, commissioning, and delivery of services that best meet the needs of individual patients with PH.

Reference

Keen C, Harrop D, Hashmi-Greenwood MN, Kiely DG, Yorke J, Sage K. Outcome measures used in studies of rehabilitation in pulmonary hypertension: a systematic review. Ann Am Thorac Soc. Published online September 18, 2020. doi: 10.1513/AnnalsATS.202005-541OC 

Topics:

Pulmonary Hypertension

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more